In the real world, there are all kinds of reasons people stop taking drugs
False and Misleading Marketing: In September 2025, the FDA issued a formal warning letter to Eli Lilly for false/misleading marketing that downplayed serious health issues while promoting Zepbound for weight loss
Overeating on semaglutide can lead to discomfort such as nausea, bloating, heartburn, or stomach pain
If a person is not losing weight on Zepbound, it is likely due to: inadequate dosage lifestyle factors (diet, exercise, sleep, or stress) inconsistent use metabolic adaptation (the body adapting to lower calorie input) underlying conditions A person can talk with a healthcare professional who may adjust their plan
They used an interactive web-response system to assign all enrolled participants into semaglutide or visually matching placebo groups in a 1:1 ratio
Changes are made based on symptoms or weight